Nanalysis Scientific Corp. Announces Closing of First Tranche of Private Placement
Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF) announced the successful closing of the first tranche of its non-brokered private placement on April 21, 2023. The company issued 3,738,667 units at $0.60 each, raising gross proceeds of $2,243,200. Each unit consists of one common share and one warrant, allowing the purchase of a share at $0.80 until one year after the closure. The proceeds will enhance working capital, with a second tranche expected to close around May 1, 2023. Finders received aggregate fees of $12,600 in connection with the first closing. The securities are subject to a four-month holding period post-closing and need final acceptance from the TSX Venture Exchange.
- Raised $2,243,200 through the issuance of 3,738,667 units.
- Strengthens working capital for Nanalysis.
- None.
CALGARY, AB, April 26, 2023 /PRNewswire/ - Nanalysis Scientific Corp. ("Nanalysis" or the "Company", TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1) is pleased to announce it has closed the first tranche of its previously announced non-brokered private placement on April 21, 2023 (the "Offering").The Company has issued a total of 3,738,667 units ("Units") at a price of
The net proceeds of the Offering will be used by the Company for working capital purposes. The Company expects to close on the second tranche of the Offering on or about May 1, 2023.
Finders acting in connection with the first tranche closing received fees in the aggregate amount of
All securities issued in connection with the Offering will not be able to be traded in Canada, or through the facilities of the TSX Venture Exchange, for a period of four months and one day from the date of closing. The Offering is subject to final TSX Venture Exchange acceptance.
About Nanalysis Scientific Corp. (TSXV: NSCI, OTCQX: NSCIF, FRA: 1N1)
Nanalysis' business is what we term "MRI and NMR for industry". The Company develops and manufactures portable Nuclear Magnetic Resonance (NMR) spectrometers or analyzers for laboratory and industrial markets. The NMReady-60™ was the first full-feature portable NMR spectrometer in a single compact enclosure requiring no liquid helium or any other cryogens. The company has followed-up that initial offering with new products and continues to have a strong innovation pipeline. In 2020 Nanalysis announced the launch of its100MHz device,the most powerful and most advanced compact NMR device ever brought to market.
Nanalysis' devices are used in many industries (oil and gas, chemical, mining, pharma, biotech, flavor and fragrances, agrochemicals, law enforcement, and more) as well as numerous government and university research labs around the world. The Company continues to exploit new global market opportunities independently and with partners.
In 2022 the Company acquired K'(Prime) Technologies Inc. (KPrime), a North American sales and service company of over 40 individuals who cover scientific instrumentation for pharma, food, chemical and oil & gas customers, as well as imaging systems for security applications.
Additionally in 2022, the Company acquired a
Notice regarding Forward Looking Statements and Legal Disclaimer
This news release contains certain "forward-looking statements" within the meaning of such statements under applicable securities law relating to the use of net proceeds of the Offering, regulatory approval for the Offering and statements relating to the successful closing of the second tranche of the Offering and anticipated timing thereof and other matters ancillary or incidental to the foregoing.
All statements included herein, other than statements of historical fact, may be forward-looking information and such information involves various risks and uncertainties. Forward-looking information is often, but not always, identified by the use of words such as "anticipates", "plan", "continue", "expect", "project", "intend", "believe", "anticipate", "estimate", "may", "will", "potential", "proposed", "positioned" and other similar words, or statements that certain events or conditions "may" or "will" occur. These statements are only predictions. Various assumptions were used in drawing the conclusions or making the projections contained in the forward-looking statements throughout this news release. Forward-looking statements are based on the opinions and estimates of management at the date the statements are made and are subject to a variety of risks and uncertainties and other factors that could cause actual events or results to differ materially from those projected in the forward-looking statements. The Company is under no obligation, and expressly disclaims any intention or obligation, to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as expressly required by applicable law.
Neither TSX Venture Exchange nor its Regulation Services Provider accepts responsibility for the adequacy or accuracy of this release.
View original content:https://www.prnewswire.com/news-releases/nanalysis-scientific-corp-announces-closing-of-first-tranche-of-private-placement-301808678.html
SOURCE Nanalysis Scientific Corp.
FAQ
What was the amount raised in the private placement by Nanalysis Scientific Corp. on April 21, 2023?
What is the exercise price of the warrants issued in Nanalysis's private placement?
When is the second tranche of the private placement expected to close?
What will the proceeds from the private placement be used for by Nanalysis?
Are there any trading restrictions on the securities issued in the private placement?
